Selection of [131I]SGMIB-2Rs15d for clinical translation was based on preclinical studies demonstrating good tumor targeting and favorable biodistribution as well as therapeutic potential in HER2-expressing subcutaneous xenograft models19. Here, ERBB2 is linked to neoplasm.